Prescription drug · NDA
Uptravi (Selexipag) NDC 66215-718
Selexipag 1800 ug/10mL · Injection, Powder, For solution · Intravenous · Actelion Pharmaceuticals US, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 66215-718-01 | 66215071801 | 1 VIAL, SINGLE-DOSE in 1 CARTON (66215-718-01) / 10 mL in 1 VIAL, SINGLE-DOSEMarketed from Jul 29, 2021 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Uptravi
- Generic name (nonproprietary)
- selexipag
- Active ingredients
- Selexipag — 1800 ug/10mL
- Dosage form
- Injection, Powder, For solution
- Route
- Intravenous
- Labeler
- Actelion Pharmaceuticals US, Inc.NDC labeler code 66215
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 214275
- Marketing start
- Listing expires
- Other FDA classes
- Prostacyclin Receptor Agonists (Mechanism)
- Identifiers
- Product ID 66215-718_7c54a125-9778-41f5-b92c-181711e22e06SPL ID 7c54a125-9778-41f5-b92c-181711e22e06SPL set ID a7a23b87-f892-4e2c-8e2e-ebf841220f90RxCUI 1729007, 1729013, 1729027, 1729029, 1729031, 1729033, 1729045, 1729047, 1729051, 1729053, 1729055, 1729057, 1729059, 1729061, 1729063, 1729065, 1729075, 1729076, 2565271, 2565275, 2744282, 2744284, 2744286, 2744288UNII 5EXC0E384LUPC 0366215612064, 0366215610060, 0366215604069, 0366215910146, 0366215606063, 0366215614068, 0366215616062
- Pharmacologic class
- Prostacyclin Receptor Agonist
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N466215071801followed by a unit qualifier and the quantityPackage 66215-0718-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
UPTRAVI is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I): In adults to delay disease progression and reduce the risk of hospitalization for PAH. ( 1.1 ) In pediatric patients aged 2 years and older. UPTRAVI reduces NT-proBNP and is expected to delay disease progression and reduce the risk of hospitalization for PAH. ( 1.1 ) 1.1 Pulmonary Arterial Hypertension Adult Patients UPTRAVI is indicated for the treatment of pulmonary arterial hypertension in adults (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH. Effectiveness of UPTRAVI tablets was established in a long-term study in ad…
Excerpt only. Read the full label for complete information.
About NDC 66215-718
- What is NDC 66215-718?
- 66215-718 is the product NDC for Uptravi (selexipag), Selexipag 1800 ug/10mL injection, powder, for solution, listed with the FDA by Actelion Pharmaceuticals US, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Uptravi (Selexipag).
- What is the active ingredient?
- Selexipag.
- Who is the labeler?
- Actelion Pharmaceuticals US, Inc., NDC labeler code 66215. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Uptravi?
- 10 other product NDCs are listed under this name. See all Uptravi NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Uptravi products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Uptraviselexipag | Selexipag 100 ug/1 | Tablet, Film coatedOral | Actelion Pharmaceuticals US, Inc. | 66215-910 | 66215-0910-14 |
| Uptraviselexipag | Selexipag 150 ug/1 | Tablet, Film coatedOral | Actelion Pharmaceuticals US, Inc. | 66215-915 | 66215-0915-14 |
| Uptraviselexipag | Selexipag 200 ug/1 | Tablet, CoatedOral | Actelion Pharmaceuticals US, Inc. | 66215-602 | 66215-0602-0666215-0602-14 |
| Uptraviselexipag | Selexipag 400 ug/1 | Tablet, CoatedOral | Actelion Pharmaceuticals US, Inc. | 66215-604 | 66215-0604-06 |
| Uptraviselexipag | Selexipag 600 ug/1 | Tablet, CoatedOral | Actelion Pharmaceuticals US, Inc. | 66215-606 | 66215-0606-06 |
| Uptraviselexipag | Selexipag 800 ug/1 | Tablet, CoatedOral | Actelion Pharmaceuticals US, Inc. | 66215-608 | 66215-0608-06 |
| Uptraviselexipag | Selexipag 1000 ug/1 | Tablet, CoatedOral | Actelion Pharmaceuticals US, Inc. | 66215-610 | 66215-0610-06 |
| Uptraviselexipag | Selexipag 1200 ug/1 | Tablet, CoatedOral | Actelion Pharmaceuticals US, Inc. | 66215-612 | 66215-0612-06 |
| Uptraviselexipag | Selexipag 1400 ug/1 | Tablet, CoatedOral | Actelion Pharmaceuticals US, Inc. | 66215-614 | 66215-0614-06 |
| Uptraviselexipag | Selexipag 1600 ug/1 | Tablet, CoatedOral | Actelion Pharmaceuticals US, Inc. | 66215-616 | 66215-0616-06 |